HDAC9 and gastric cancer: NCI-N87 gastric cancer cells were less sensitive than the MCF10A breast cells to the pan-HDAC inhibitors tested, as demonstrated by a higher IC50 (Table S5), but the differential between the isogenic lines was more pronounced in NCI-N87 cells (NCI-N87-WT vs. NCI-N87- CDH1−/−: entinostat up to 36% (Figure 2A), pracinostat 29% (Figure 2B), mocetinostat 38% (Figure 2C) and vorinostat 23% (Figure 2D)).